IOLCP Q1FY27 Profit Rises to ₹64.48 Crore on 37% Revenue Growth
IOLCP reported Q1FY27 consolidated profit after tax of ₹64.40 crore, up from ₹33.93 crore in Q1FY26. Total income increased to ₹764.44 crore from ₹559.06 crore. Standalone profit after tax was ₹64.48 crore. Standalone revenue from operations stood at ₹756.26 crore.
The substantial growth in profit and revenue is a material development for the company's financial health and investor outlook.
The company reported a significant increase in profit and revenue for the quarter compared to the previous year, indicating strong financial performance.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a consolidated profit after tax of ₹64.40 crore, a significant increase from ₹33.93 crore in the corresponding quarter of the previous year.
Total income for the quarter grew by 37% to ₹764.44 crore, up from ₹559.06 crore in Q1FY26. The standalone profit after tax stood at ₹64.48 crore for the quarter ended June 30, 2026, compared to ₹33.96 crore in the same period last year.
The company's revenue from operations also saw a substantial rise. Standalone revenue from operations was ₹756.26 crore for Q1FY27, an increase from ₹551.69 crore in Q1FY26. Consolidated revenue from operations also reached ₹756.26 crore for the quarter.
Earnings per share (EPS) for the quarter ended June 30, 2026, were ₹2.20 on a standalone basis and ₹2.19 on a consolidated basis, up from ₹1.16 in the prior year's quarter.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.